Fortune Brands plans Deerfield headquarters expansion, hundreds of new jobs; ‘A great endorsement of Lake County’
Fortune Brands recently announced it will consolidate its U.S offices into one headquarters, taking over two of three office ...
Stockhouse14d
Kyverna Therapeutics to Highlight Near-Term Strategic Priorities and Key Milestones at the 43rd Annual J.P. Morgan Healthcare Conference
EMERYVILLE, Calif., Jan. 13, 2025 /PRNewswire/ -- Kyverna Therapeutics, Inc. (Kyverna, NASDAQ: KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with ...
Seeking Alpha14d
TG Therapeutics: Subcutaneous Briumvi Data A Key Near-Term Catalyst
A confirmation in "early" 2025 that the company has developed a competitive subcutaneous formulation of Briumvi is another potential near-term catalyst for the stock. Further positives include the ...
PC Magazine14d
Amazon Prime Membership: What Is Included and How Much Does it Cost?
The cost of an Amazon Prime membership differs depending on how you want to pay. As of February 2022, it costs $14.99 per month or $139 per year, so with the annual rate, you save $40.We've seen a ...
Morningstar15d
Kyverna Therapeutics to Highlight Near-Term Strategic Priorities and Key Milestones at the 43rd Annual J.P. Morgan Healthcare Conference
About Kyverna Therapeutics Kyverna Therapeutics, Inc. (Nasdaq: KYTX) is a clinical-stage biopharmaceutical company focused on liberating patients through the curative potential of cell therapy.
WMBB15d
Kyverna Therapeutics to Highlight Near-Term Strategic Priorities and Key Milestones at the 43rd Annual J.P. Morgan Healthcare Conference
EMERYVILLE, Calif., Jan. 13, 2025 /PRNewswire/ -- Kyverna Therapeutics, Inc. (Kyverna, NASDAQ: KYTX), a clinical-stage biopharmaceutical company focused on developing ...
Mena FN15d
Kyverna Therapeutics To Highlight Near-Term Strategic Priorities And Key Milestones At The 43Rd Annual J.P. Morgan Healthcare Conference
Jan. 13, 2025 /PRNewswire/ -- Kyverna Therapeutics, Inc. (Kyverna, NASDAQ: KYTX ), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune ...